Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

PHI in the Early Detection of Prostate Cancer

R. Fuchsova, O. Topolcan, J. Windrichova, M. Hora, O. Dolejsova, L. Pecen, P. Kasik, J. Novak, M. Casova, J. Smejkal,

. 2015 ; 35 (9) : 4855-7.

Language English Country Greece

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16020421

AIM: To evaluate changes in the serum levels of prostate specific antigen (PSA), %free PSA and -2proPSA biomarkers, and prostate health index (PHI) in the diagnostic algorithm of early prostate cancer. PATIENTS AND METHODS: The Immunoanalytical Laboratory of the University Hospital in Pilsen examined sera from 263 patients being treated at the Hospital's Urology Department with suspected prostate cancer who had undergone biopsies and were divided into a benign and malignant group. The monitored biomarkers were measured using chemiluminescence. All statistical analyses were calculated using the SAS software. RESULTS: We found statistically significantly increased levels of -2proPSA, PHI and PSA and decreased levels of %freePSA in patients diagnosed with prostate cancer by prostate biopsy vs. patients with benign prostatic hypertrophy (median values: -2proPSA: 16 vs. 21 ng/l, PHI: 35 vs. 62, total PSA: 7.2 vs. 7.7 μg/l and %free PSA: 16.7 vs. 11.7%). Receiver operating characteristic curves showed the best performance for PHI compared to other markers. CONCLUSION: The assessment of -2proPSA and the calculation of PHI appear to be of great benefit for a more accurate differential diagnosis of benign hyperplasia and prostate cancer.

000      
00000naa a2200000 a 4500
001      
bmc16020421
003      
CZ-PrNML
005      
20170118084550.0
007      
ta
008      
160722s2015 gr f 000 0|eng||
009      
AR
035    __
$a (PubMed)26254378
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Fuchsova, Radka $u Department of Nuclear Medicine, Immunoanalytical Laboratory, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic fuchsovar@fnplzen.cz.
245    10
$a PHI in the Early Detection of Prostate Cancer / $c R. Fuchsova, O. Topolcan, J. Windrichova, M. Hora, O. Dolejsova, L. Pecen, P. Kasik, J. Novak, M. Casova, J. Smejkal,
520    9_
$a AIM: To evaluate changes in the serum levels of prostate specific antigen (PSA), %free PSA and -2proPSA biomarkers, and prostate health index (PHI) in the diagnostic algorithm of early prostate cancer. PATIENTS AND METHODS: The Immunoanalytical Laboratory of the University Hospital in Pilsen examined sera from 263 patients being treated at the Hospital's Urology Department with suspected prostate cancer who had undergone biopsies and were divided into a benign and malignant group. The monitored biomarkers were measured using chemiluminescence. All statistical analyses were calculated using the SAS software. RESULTS: We found statistically significantly increased levels of -2proPSA, PHI and PSA and decreased levels of %freePSA in patients diagnosed with prostate cancer by prostate biopsy vs. patients with benign prostatic hypertrophy (median values: -2proPSA: 16 vs. 21 ng/l, PHI: 35 vs. 62, total PSA: 7.2 vs. 7.7 μg/l and %free PSA: 16.7 vs. 11.7%). Receiver operating characteristic curves showed the best performance for PHI compared to other markers. CONCLUSION: The assessment of -2proPSA and the calculation of PHI appear to be of great benefit for a more accurate differential diagnosis of benign hyperplasia and prostate cancer.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a plocha pod křivkou $7 D019540
650    _2
$a nádorové biomarkery $x krev $7 D014408
650    _2
$a časná detekce nádoru $7 D055088
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prostata $x patologie $7 D011467
650    _2
$a prostatický specifický antigen $x krev $7 D017430
650    _2
$a nádory prostaty $x krev $x diagnóza $7 D011471
650    _2
$a ROC křivka $7 D012372
650    _2
$a senzitivita a specificita $7 D012680
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Topolcan, Ondrej $u Department of Nuclear Medicine, Immunoanalytical Laboratory, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Windrichová, Jindra $u Department of Nuclear Medicine, Immunoanalytical Laboratory, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. $7 xx0209887
700    1_
$a Hora, Milan $u Department of Urology, University Hospital in Pilsen, Pilsen, Czech Republic.
700    1_
$a Dolejsova, Olga $u Department of Urology, University Hospital in Pilsen, Pilsen, Czech Republic.
700    1_
$a Pecen, Ladislav $u Department of Nuclear Medicine, Immunoanalytical Laboratory, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Kasik, Petr $u Department of Nuclear Medicine, Immunoanalytical Laboratory, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Novak, Jaroslav $u Department of Nuclear Medicine, Immunoanalytical Laboratory, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Casova, Miroslava $u Department of Nuclear Medicine, Immunoanalytical Laboratory, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Smejkal, Jiri $u Department of Nuclear Medicine, Immunoanalytical Laboratory, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 35, č. 9 (2015), s. 4855-7
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26254378 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20170118084657 $b ABA008
999    __
$a ok $b bmc $g 1155091 $s 944949
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 35 $c 9 $d 4855-7 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20160722

Find record

Citation metrics

Archiving options